Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer
ConditionAdvanced Breast Cancer
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexFemale
Age18+
SponsorWenjin Yin
About this trial
This is a prospective, randomised, controlled, multicentre study to evaluate the efficacy and safety of Iparomlimab and Tuvonralimab (QL1706) in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer.
Eligibility criteria
Qualifiers
Female, age≥18 years old
Expected survival ≥12 weeks
ECOG 0-1
Pathologically confirmed recurrent or metastatic breast cancer not amenable to curative surgery
Disqualifiers
During pregnancy and lactation
Patients with central nervous system metastasis
Trial design
Treatments tested in this trial
- QL1706
- CDK4/6 inhibitor
- Fulvestrant
Treatment groups
123 Participants
are divided into 2 treatment groupsSponsors and collaborators
Wenjin Yin
Lead sponsor
RenJi Hospital
Sponsor institution
Source ClinicalTrials.gov